Related Experiment Video
Updated: Jun 23, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Management of cardiac adverse events occurring with sunitinib treatment
Manuela Schmidinger1, Andja Bojic, Ursula M Vogl
1Medical University of Vienna, Department of Medicine I and Cancer Center, Clinical Division of Oncology, Waehringer Guertel 18-20, A-1090 Vienna, Austria. manuela.schmidinger@meduniwien.ac.at
Background:
Sunitinib malate is the reference standard of care for the first-line treatment of metastatic renal cell carcinoma (mRCC). Cardiovascular adverse events (AEs) have been observed with sunitinib treatment. Here, we present the case report of a 49-year-old male patient with mRCC in whom cardiac AEs experienced during sunitinib treatment were successfully managed. The patient was at poor prognostic risk, with an Eastern Cooperative Oncology Group performance status of 3.
Results:
The patient was treated with sunitinib 50 mg/day (4 weeks on treatment followed by 2 weeks off treatment; Schedule 4/2) following lung and bone metastases. Cardiac AEs occurred following sunitinib initiation. These events were resolved with cardiovascular co-medication. Sunitinib improved the patient's quality of life and performance status, with a prolonged duration of treatment of 24 months.
Conclusion:
This case indicates that cardiac AEs should not be a barrier to the effective use of sunitinib in mRCC.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Kidney Injury VI: Nursing Management
Cardiac Catheterization I: Pre-Procedure Overview
Heart Failure VI: Adjunct Therapies
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Pericarditis IV: Nursing Management
